Literature DB >> 18470679

Antimetastatic effect of suicide gene therapy for mouse mammary cancers requires T-cell-mediated immune responses.

Masa-Aki Shibata1, Junji Morimoto, Kanako Akamatsu, Yoshinori Otsuki.   

Abstract

These experiments were conducted to investigate whether the antimetastatic effects of HSVtk/GCV therapy involve T-cell-mediated immune responses. In the first experiment, immunocompetent syngeneic mice were inoculated with metastatic mammary cancers, then given a direct intratumoral injection of a plasmid vector containing a suicide gene (pHSVtk) or control vector once a week for 8 weeks. Gene electrotransfer treatment was applied to the tumors, and mice were administered ganciclovir (GCV) using a mini-osmotic pump. At the end of the experiment, tumor volume was significantly lower in the pHSVtk/GCV group. Macrophage accumulations were frequently observed in the peripheries of the necrotic regions in pHSVtk-transfected mice. Levels of CD4 and CD8 proteins in tumors were higher in the pHSVtk/GCV group than in the control group. Interleukin (IL)-12 mRNA levels tended to be higher in tumors in the pHSVtk/GCV group, but there were large variations. Tumor microvessel density was significantly lower in the pHSVtk/GCV group. The numbers of dilated lymphatic vessels containing intraluminal tumor cells tended to be higher in the pHSVtk/GCV group. However, vascular endothelial growth factor (VEGF)-A and VEGF-C mRNA levels in tumors were similar in the control and pHSVtk/GCV groups. In the second experiment, tumor volume and metastatic parameters were compared for immunocompetent syngeneic mice and immunodeficient athymic mice (without an intact T-cell system) given pHSVtk/GCV therapy. Although tumor volumes were significantly smaller in both syngeneic and athymic mice given pHSVtk/GCV therapy, the inhibition ratios (relative to control mice) were much greater in syngeneic mice than in athymic mice. No suppression of metastasis to the lymph nodes and lungs was observed for athymic mice given pHSVtk/GCV therapy. Our data suggest that HSVtk/GCV suicide gene therapy exerts an antimetastatic effect via a T-cell-mediated immune response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18470679     DOI: 10.1007/s00795-007-0388-1

Source DB:  PubMed          Journal:  Med Mol Morphol        ISSN: 1860-1499            Impact factor:   2.309


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  New murine mammary tumor cell lines.

Authors:  J Morimoto; S Imai; S Haga; Y Iwai; M Iwai; S Hiroishi; N Miyashita; K Moriwaki; H L Hosick
Journal:  In Vitro Cell Dev Biol       Date:  1991-05

Review 3.  Experimental gene therapy in mammary and urinary bladder cancer using electrogene transfer.

Authors:  Masa-Aki Shibata; Junji Morimoto; Yuko Ito; Ken Kusakabe; Yoshinori Otsuki
Journal:  Med Electron Microsc       Date:  2004-12

Review 4.  The roles of IFN gamma in protection against tumor development and cancer immunoediting.

Authors:  Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Cytokine Growth Factor Rev       Date:  2002-04       Impact factor: 7.638

5.  Suppression of murine mammary carcinoma growth and metastasis by HSVtk/GCV gene therapy using in vivo electroporation.

Authors:  Masa-Aki Shibata; Junji Morimoto; Yoshinori Otsuki
Journal:  Cancer Gene Ther       Date:  2002-01       Impact factor: 5.987

6.  Cancer gene therapy with HSV-tk/GCV system depends on T-cell-mediated immune responses and causes apoptotic death of tumor cells in vivo.

Authors:  S Kuriyama; M Kikukawa; K Masui; H Okuda; T Nakatani; T Akahane; A Mitoro; K Tominaga; H Tsujinoue; H Yoshiji; S Okamoto; H Fukui; K Ikenaka
Journal:  Int J Cancer       Date:  1999-10-29       Impact factor: 7.396

7.  VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer.

Authors:  R Valtola; P Salven; P Heikkilä; J Taipale; H Joensuu; M Rehn; T Pihlajaniemi; H Weich; R deWaal; K Alitalo
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

8.  The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified.

Authors:  S M Freeman; C N Abboud; K A Whartenby; C H Packman; D S Koeplin; F L Moolten; G N Abraham
Journal:  Cancer Res       Date:  1993-11-01       Impact factor: 12.701

9.  Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors.

Authors:  P Salven; A Lymboussaki; P Heikkilä; H Jääskela-Saari; B Enholm; K Aase; G von Euler; U Eriksson; K Alitalo; H Joensuu
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

10.  Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice.

Authors:  K Boggio; G Nicoletti; E Di Carlo; F Cavallo; L Landuzzi; C Melani; M Giovarelli; I Rossi; P Nanni; C De Giovanni; P Bouchard; S Wolf; A Modesti; P Musiani; P L Lollini; M P Colombo; G Forni
Journal:  J Exp Med       Date:  1998-08-03       Impact factor: 14.307

View more
  5 in total

1.  Apoptotic effects of Tian-Long compound on endometrial adenocarcinoma cells in vitro.

Authors:  Zhong-Lian Li; Syoko Morishima; Jin-Tian Tang; Yoshinori Otsuki
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

2.  Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.

Authors:  Shoko Morishima; Masa-Aki Shibata; Masahide Ohmichi; Yoshinori Otsuki
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

3.  Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.

Authors:  Zvi G Fridlender; Jing Sun; Sunil Singhal; Veena Kapoor; Guanjun Cheng; Eiji Suzuki; Steven M Albelda
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

4.  Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Authors:  Theresa Falls; Dominic Guy Roy; John Cameron Bell; Marie-Claude Bourgeois-Daigneault
Journal:  ILAR J       Date:  2016

5.  Oncolytic adenoviruses armed with thymidine kinase can be traced by PET imaging and show potent antitumoural effects by ganciclovir dosing.

Authors:  Daniel Abate-Daga; Nuria Andreu; Juan Camacho-Sánchez; Ramon Alemany; Raúl Herance; Olga Millán; Cristina Fillat
Journal:  PLoS One       Date:  2011-10-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.